Balchem/$BCPC
1D1W1MYTD1Y5YMAX
Capital at risk
About Balchem
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
- Ticker
- $BCPC
- Sector
- Materials
- Primary listing
- NASDAQ
- Employees
- 1,379
- Headquarters
- Montvale, United States
- Website
- www.balchem.com
Balchem Metrics
BasicAdvanced
$5.4B
33.57
$5.08
0.81
$0.96
0.56%
Price and volume
Market cap
$5.4B
Beta
0.81
52-week high
$183.90
52-week low
$139.17
Average daily volume
180K
Dividend rate
$0.96
Financial strength
Current ratio
2.665
Quick ratio
1.456
Long term debt to equity
11.671
Total debt to equity
11.671
Dividend payout ratio (TTM)
18.73%
Interest coverage (TTM)
25.54%
Profitability
EBITDA (TTM)
269.412
Gross margin (TTM)
36.29%
Net profit margin (TTM)
15.14%
Operating margin (TTM)
20.35%
Effective tax rate (TTM)
22.59%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
8.21%
Return on equity (TTM)
12.79%
Valuation
Price to earnings (TTM)
33.575
Price to revenue (TTM)
5.003
Price to book
4.18
Price to tangible book (TTM)
15.94
Price to free cash flow (TTM)
31.703
Free cash flow yield (TTM)
3.15%
Free cash flow per share (TTM)
5.38
Dividend yield (TTM)
0.56%
Forward dividend yield
0.56%
Growth
Revenue change (TTM)
10.14%
Earnings per share change (TTM)
16.53%
3-year revenue growth (CAGR)
4.90%
10-year revenue growth (CAGR)
7.10%
3-year earnings per share growth (CAGR)
18.28%
10-year earnings per share growth (CAGR)
11.18%
3-year dividend per share growth (CAGR)
10.58%
10-year dividend per share growth (CAGR)
10.94%
What the Analysts think about Balchem
Analyst ratings (Buy, Hold, Sell) for Balchem stock.
Analyst projections of the future price of Balchem stock.
Bulls say / Bears say
Record consolidated Q2 2026 net sales of $284.0 million (up 11.2% year-over-year), GAAP net earnings of $44.6 million (up 16.6%), and adjusted EBITDA of $77.9 million (up 12.6%), driven by broad-based segment growth (SEC)
Strong balance sheet featuring net debt of $88.8 million and a net leverage ratio of 0.3 times trailing twelve-month adjusted EBITDA, underpinning financial flexibility for strategic investments (SEC)
Amendment of revolving credit facility on July 24, 2026, increased borrowing capacity from $550 million to $650 million and extended maturity to July 24, 2031, enhancing liquidity for growth, innovation, and M&A (SEC)
Higher manufacturing input costs, driven by global inflation and geopolitical tensions, led to modest margin compression across all segments in Q2 2026, partially offsetting revenue gains (SEC)
Heavy reliance on the Human Nutrition & Health segment—which generated $176.9 million or 62% of Q2 2026 sales—exposes Balchem to potential volatility in consumer nutrition demand (SEC)
Volatility in ethylene oxide prices—up approximately 18% year-over-year in Q1 2025—highlights ongoing raw material cost risks that could further pressure margins if costs cannot be fully passed through (MatrixBCG)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Balchem Financial Performance
Revenues and expenses
Balchem Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Balchem
AllUSDGBPEUR
Fund name | Fund size | $BCPC weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.29% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.29% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.18% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.17% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.